YourInfoDaily
GOA Therapeutics Wants Up to $300 Million From Everyday Investors to Build an 'Alcohol Antidote'
The West Palm Beach biotech's SEC-qualified offering opens Oct. 15 at $15 a share, but its lead drug has so far only been tested in pigs.
Anyone who has watched a night out go sideways knows the problem: once alcohol is in the bloodstream, there is not much medicine can do except wait. GOA Therapeutics thinks it can change that, and it is asking everyday investors to help pay for it.
The West Palm Beach, Florida, biotech said the U.S. Securities and Exchange Commission has qualified its Tier 2 Regulation A offering, which opens to the public on Thursday, October 15, 2026, at $15.00 per share. Combined with separate exempt offerings, GOA is contemplating up to roughly $300 million in total stock sales. The Regulation A portion alone is capped at 5 million shares, or up to $75 million.
What GOA Therapeutics Is Building
The company's lead candidate, GOA26, is an investigational drug for acute alcohol intoxication and alcohol poisoning. It is designed to lower blood alcohol concentration and sequester acetaldehyde, the toxic byproduct the body creates when it breaks down alcohol. GOA plans to develop it first as an intravenous treatment for hospital emergency departments and trauma centers, not as a hangover pill sold at the corner store.
"No family should lose someone they love because they had too much to drink," co-founder and CEO Andrew Altschuler said in the announcement. He added that today "there is no FDA-approved medicine that directly and rapidly removes alcohol from the bloodstream" for patients with acute intoxication.
The Data So Far
The evidence is early. In preclinical porcine studies modeling severe intoxication, GOA reported that blood alcohol concentration was 61.3% lower in the GOA26 group than in controls after 20 minutes. The company itself notes those animal results do not establish safety or efficacy in humans, and GOA26 has not been approved by the FDA or any other regulator.
Proceeds from the offering are intended to move GOA26 "into and through clinical development," which means human trials are still ahead.
Why the Public Offering Route Matters
Regulation A+ lets private companies sell shares to the general public, not just accredited investors, under lighter rules than a traditional IPO. It has become a popular tool for consumer brands and, increasingly, for early-stage biotechs that want to tap a community of supporters alongside, or instead of, venture capital. DealMaker Securities LLC is serving as broker-dealer for the Regulation A portion.
The model widens access, but it also shifts risk onto retail buyers. GOA's own disclosures warn that investors could lose their entire investment, that there is no public trading market for the shares, and that there is no assurance the offerings will reach the contemplated $300 million. SEC qualification is not an endorsement of the company or its materials.
The Bigger Picture
Alcohol poisoning sends patients to emergency rooms every day, and treatment is largely supportive care: fluids, monitoring and time. A drug that could actively pull alcohol out of the blood would be a true first for emergency medicine, which is exactly why the pitch is resonating with would-be backers.
Whether GOA26 can repeat its animal results in people is the multi-hundred-million-dollar question. For now, GOA Therapeutics is betting that a compelling mission and a $15 share price can fund the trials needed to find out.
Source
GlobeNewswire — "SEC Qualifies GOA Therapeutics' Public Offering to Sell Up to $300 Million in Stock; Set for Launch October 15"